Clinical trial
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
NCT00283478 · Kentuckiana Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00283478 |
|---|---|
| Title | Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer |
| Official title | Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer. |
| Lead sponsor | Kentuckiana Cancer Institute, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Iscar Quercus, Gemcitabine |
| Enrollment | 20 |
| Start date | May 1, 2004 |
| Completion | Apr 1, 2007 |
| First posted | Jan 30, 2006 |
| Last update posted | Oct 31, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: